Overview

A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion

Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-06-22
Target enrollment:
Participant gender:
Summary
This is a phase II, randomised, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of HSK31858 in patients with airway mucus hypersecretion in chronic airway inflammatory diseases
Phase:
PHASE2
Details
Lead Sponsor:
Haisco Pharmaceutical Group Co., Ltd.